NCT07099391View on ClinicalTrials.gov

A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

July 24, 2025

Primary Completion Date

July 24, 2029

Study Completion Date

July 24, 2029

Conditions
Multiple Myeloma
Interventions
DRUG

Dara-RVd

This study is a phase 1/2 study design of alternating 6 cycles of Dara-RVd/Tec-RVd induction therapy

DRUG

Tec-RVd

This study is a phase 1/2 study design of alternating 6 cycles of Dara-RVd/Tec-RVd induction therapy

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities), Commack

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT07099391 - A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma | Biotech Hunter | Biotech Hunter